Forefront Analytics LLC Boosts Stock Holdings in Zura Bio Limited (NASDAQ:ZURA)

Forefront Analytics LLC lifted its stake in Zura Bio Limited (NASDAQ:ZURA) by 74.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,734 shares of the company’s stock after purchasing an additional 22,924 shares during the period. Forefront Analytics LLC’s holdings in Zura Bio were worth $134,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ZURA. American Century Companies Inc. acquired a new stake in Zura Bio in the 4th quarter valued at about $27,000. Prudential Financial Inc. purchased a new stake in shares of Zura Bio during the fourth quarter worth approximately $28,000. XTX Topco Ltd acquired a new stake in Zura Bio in the fourth quarter valued at approximately $44,000. SG Americas Securities LLC lifted its stake in Zura Bio by 51.6% in the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock worth $58,000 after acquiring an additional 7,828 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Zura Bio by 68.6% during the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock worth $58,000 after acquiring an additional 9,379 shares in the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ZURA. Chardan Capital reduced their price objective on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. Oppenheimer cut their price target on Zura Bio from $19.00 to $17.00 and set an “outperform” rating on the stock in a research note on Friday. Guggenheim reaffirmed a “buy” rating and set a $15.00 price objective on shares of Zura Bio in a research report on Wednesday, March 26th. Finally, HC Wainwright reissued a “buy” rating on shares of Zura Bio in a research report on Thursday, April 3rd. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Zura Bio presently has an average rating of “Buy” and an average price target of $14.33.

Zura Bio Price Performance

ZURA stock opened at $1.21 on Friday. The company has a market cap of $82.73 million, a price-to-earnings ratio of -2.28 and a beta of 0.05. The company has a fifty day moving average price of $1.28 and a 200 day moving average price of $2.11. Zura Bio Limited has a 12 month low of $0.97 and a 12 month high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). As a group, analysts anticipate that Zura Bio Limited will post -0.65 earnings per share for the current year.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.